Taletrectinib: TRUST in the Continued Evolution of Treatments for <i>ROS1</i> Fusion-Positive Lung Cancer.

Abstract

In the article that accompanies this editorial, Li et al. report results from the phase 2 trial TRUST-I, in which taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), demonstrated robust systemic and intracranial efficacy, ability to overcome on-target <i>ROS1</i> resistance mutations, and relatively low rates of neurologic adverse events among TKI-naïve and crizotinib-pretreated patients in China with advanced <i>ROS1</i> fusion-positive (ROS1+) non-small cell lung cancer (NSCLC). These findings represent another step forward in the efforts to improve outcomes for patients with ROS1+ NSCLC, and the global phase 2 trial TRUST-II is ongoing to further explore the efficacy and safety of taletrectinib in a broader population.